March 2021 - QuartzBio

March 8, 2021 — At last week’s SCOPE 2021 virtual summit for clinical operations executives and their partners, an overarching theme was the increased speed of clinical operations in response to the COVID-19 pandemic.

“Speed — is this the new normal? Can we as organizations support that ramped-up speed … with the resources that we all have?” asked moderator Michael Tanen, Director, Clinical Biomarker Specimen Management, Merck & Co., at Tuesday’s panel discussion in the Clinical Biomarkers Operations & Innovations track.

QuartzBio’s SVP of Data Management and Systems Integration, Tobi Guennel, joined leaders from Bristol-Myers Squibb, Eli Lilly, AbbVie, and Covance for this live panel.

March 5, 2021 — Applying algorithms to interconnected biomarker and clinical data can yield scientific insights, not only into therapeutic mechanisms, but also into predicting long-term response to treatment.

In a collaboration with investigators at Janssen, the QuartzBio team sought to identify genetic markers correlated with protection against chronic hepatitis B early relapse in patients after withdrawal from treatment. The team identified several genes that were, for the first time, associated with protection against early onset of relapse.

View the poster

Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments. Precision for Medicine is part of Precision Medicine Group, with 3,000 employees in 40 locations.

Web Design and Development by RainCastle Communications.